argenx to Present at Upcoming Investor Conferences
argenx (Euronext & Nasdaq: ARGX) is a global immunology company focused on improving the lives of those affected by severe autoimmune diseases. The company has announced that its management team will be attending several important investor conferences this September. These events aim to raise awareness of argenx's innovative approaches and therapeutic advancements.
Conference Participation Details
The management team at argenx is looking forward to connecting with investors and stakeholders at the following conferences:
2024 Wells Fargo Healthcare Conference
The first event is the 2024 Wells Fargo Healthcare Conference, featuring a fireside chat on Wednesday, September 4, 2024, at 1:30 p.m. ET. This conference will take place in Boston and provides a valuable opportunity for the management team to discuss their strategic direction and clinical advancements.
Morgan Stanley 22nd Annual Global Healthcare Conference
Next, the team will be at the Morgan Stanley 22nd Annual Global Healthcare Conference on Thursday, September 5, 2024. This fireside chat is set for 4:50 p.m. ET in New York, offering another chance for the company to highlight its developments in immunology.
Baird 2024 Global Healthcare Conference
Finally, argenx will participate in the Baird 2024 Global Healthcare Conference on Tuesday, September 10, 2024, at 9:40 a.m. ET in New York. These engagements are vital for building relationships with investors and sharing insights about their ongoing research.
About argenx
Founded with the goal of addressing severe autoimmune diseases, argenx specializes in immunology and is dedicated to transforming scientific breakthroughs into effective treatments. Through their Immunology Innovation Program (IIP), the company collaborates with leading academic researchers to develop innovative antibody-based therapies.
Argens has reached significant milestones, including the commercialization of the first approved neonatal Fc receptor (FcRn) blocker, which is now available in various markets worldwide, including the U.S., Japan, Israel, the European Union, the United Kingdom, China, and Canada. The company is actively progressing its clinical trials, assessing efgartigimod for several severe autoimmune diseases while also exploring a range of experimental medicines within its therapeutic franchises.
For more information about argenx and its innovative approaches, interested individuals are encouraged to visit their official website.
Contact Information
For further information, please contact:
Media Inquiries:
Ben Petok
bpetok@argenx.com
Investor Relations:
Alexandra Roy (US)
aroy@argenx.com
Lynn Elton (EU)
lelton@argenx.com
Frequently Asked Questions
What is the purpose of argenx's participation in investor conferences?
The purpose is to engage with investors, provide insights into their advancements in immunology, and discuss their strategic initiatives.
When and where will the first investor conference take place?
The first conference, the Wells Fargo Healthcare Conference, is set for September 4, 2024, in Boston at 1:30 p.m. ET.
What notable products has argenx developed?
Argens has developed and is commercializing the first approved neonatal Fc receptor blocker, aimed at enhancing treatment options for severe autoimmune diseases.
Who should attend these investor conferences?
Investors, analysts, and stakeholders interested in the latest advancements in healthcare and immunology are encouraged to participate.
Where can I find more information about argenx?
More information about argenx, including their research and developments, can be found on their official website.
